6844.TWO · NORBEL
Taiwan · RS rating 9 · As of 2026-10-08
| Price | 56.10 TWD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 11 / 26 / 9 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 12 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (53) |
| EPS growth Q/Q | -70.7% |
| Sales growth Q/Q | +1.0% |
| Distance from 52-week high | +39.6% |
| Market cap (USD) | $66.8M |